Evidence map›Paper›PMID 23867982›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013

Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.

Paul Newhouse, Kimberly Albert, Robert Astur, Julia Johnson, Magdalena Naylor, Julie Dumas

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. The Role of Estrogen in Brain and Cognitive Aging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Paul Newhouse1] Vanderbilt Center for Cognitive Medicine, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA [2] Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT, USA.
Kimberly Albert
Robert Astur
Julia Johnson
Magdalena Naylor
Julie Dumas
University of Vermont · USVanderbilt University · USUniversity of Connecticut · USUniversity of Massachusetts Chan Medical School · US

Funding

Estrogen Effects on Cholinergic Function in Older WomenR01AG021476 · NIA · VANDERBILT UNIVERSITY · PI NEWHOUSE, PAUL A. · 2003 to 2013
$4.2M
Hormone and Neurotransmitter Interactions in Cognitive AgingK01AG030380 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI DUMAS, JULIE A · 2008 to 2012
$650k
NIA NIH HHS K01 AG030380NIA NIH HHS R01 AG021476PHS HHS K01 030380PHS HHS M01-00109
6 · The paper itself

Abstract

Tamoxifen (TMX) is a selective estrogen receptor modulator that is used as an estrogen receptor antagonist for the treatment and prevention of breast cancer. Whether TMX has antagonist activities in the human brain is less clear and its effects on cognitive function have not been experimentally explored. This study examined how TMX affected cognitive performance in older women using a model of anticholinergic drug-induced cognitive dysfunction. Twenty-one postmenopausal women were administered 20 mg of oral TMX or placebo for 3 months. Participants then took part in five drug challenges using the anticholinergic antinicotinic agent mecamylamine (MECA) and antimuscarinic agent scopolamine (SCOP) and were tested on a comprehensive battery including tasks of attention and psychomotor function, verbal episodic memory, and spatial navigation. After a 3-month placebo washout, participants were then crossed over to the alternate treatment and repeated the drug challenges after 3 months. Compared with placebo treatment, TMX significantly attenuated the impairment from cholinergic blockade on tasks of verbal episodic memory and spatial navigation, but effects on attentional/psychomotor tasks were more variable. Analysis by APOE genotype showed that APO ɛ4+ women showed a greater beneficial effect of TMX on reversing the cholinergic impairment than APO ɛ4- women on most tasks. This study provides evidence that TMX may act as an estrogen-like agonist to enhance cholinergic system activity and hippocampally mediated learning.

Indexed as

AgedAttentionCholinergic AntagonistsCognition DisordersEstrogen AntagonistsFemaleHumansMecamylamineMemoryMiddle AgedNeuropsychological TestsPain MeasurementPostmenopausePsychiatric Status Rating ScalesScopolamineTamoxifenCholinergic AntagonistsEstrogen AntagonistsMecamylamineScopolamineTamoxifen

Identifiers

PMID23867982
PMCPMC3828534
OpenAlexW2139918036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.